nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadobenate Dimeglumine—ALB—Abiraterone—prostate cancer	0.24	0.401	CbGbCtD
Gadobenate Dimeglumine—ALB—Estrone—prostate cancer	0.174	0.29	CbGbCtD
Gadobenate Dimeglumine—ALB—Estradiol—prostate cancer	0.0998	0.166	CbGbCtD
Gadobenate Dimeglumine—ALB—Prednisone—prostate cancer	0.0858	0.143	CbGbCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—GRHL1—prostate cancer	0.0001	0.00356	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Vitamin B12 Metabolism—SERPINE1—prostate cancer	0.0001	0.00355	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Response to elevated platelet cytosolic Ca2+—ITGB3—prostate cancer	9.75e-05	0.00346	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Folate Metabolism—ICAM1—prostate cancer	9.73e-05	0.00346	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—CLU—prostate cancer	9.7e-05	0.00344	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	9.56e-05	0.00339	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—SLC7A1—prostate cancer	9.53e-05	0.00338	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Folate Metabolism—INS—prostate cancer	8.85e-05	0.00314	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Selenium Micronutrient Network—MTHFR—prostate cancer	8.84e-05	0.00314	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—MBTPS1—prostate cancer	8.76e-05	0.00311	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—GNG5—prostate cancer	8.44e-05	0.003	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—STX4—prostate cancer	8.35e-05	0.00296	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—RAD51B—prostate cancer	8.35e-05	0.00296	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—AMACR—prostate cancer	8.31e-05	0.00295	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—DEGS1—prostate cancer	8.31e-05	0.00295	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—SRD5A2—prostate cancer	8.31e-05	0.00295	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Folate Metabolism—SERPINE1—prostate cancer	8.13e-05	0.00289	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet degranulation—EGF—prostate cancer	7.93e-05	0.00281	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—HSD17B1—prostate cancer	7.92e-05	0.00281	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	7.79e-05	0.00277	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Selenium Micronutrient Network—ICAM1—prostate cancer	7.73e-05	0.00275	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Response to elevated platelet cytosolic Ca2+—EGF—prostate cancer	7.55e-05	0.00268	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—SLC39A1—prostate cancer	7.54e-05	0.00268	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—F9—prostate cancer	7.51e-05	0.00267	CbGpPWpGaD
Gadobenate Dimeglumine—Abdominal pain—Etoposide—prostate cancer	7.5e-05	0.000201	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract infection—Doxorubicin—prostate cancer	7.5e-05	0.000201	CcSEcCtD
Gadobenate Dimeglumine—Conjunctivitis—Doxorubicin—prostate cancer	7.5e-05	0.000201	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Capecitabine—prostate cancer	7.48e-05	0.000201	CcSEcCtD
Gadobenate Dimeglumine—Syncope—Prednisone—prostate cancer	7.47e-05	0.000201	CcSEcCtD
Gadobenate Dimeglumine—Tachycardia—Capecitabine—prostate cancer	7.45e-05	0.0002	CcSEcCtD
Gadobenate Dimeglumine—Hypoaesthesia—Epirubicin—prostate cancer	7.44e-05	0.0002	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Capecitabine—prostate cancer	7.41e-05	0.000199	CcSEcCtD
Gadobenate Dimeglumine—Sweating—Doxorubicin—prostate cancer	7.39e-05	0.000199	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract disorder—Epirubicin—prostate cancer	7.39e-05	0.000198	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Capecitabine—prostate cancer	7.38e-05	0.000198	CcSEcCtD
Gadobenate Dimeglumine—Oedema peripheral—Epirubicin—prostate cancer	7.37e-05	0.000198	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Docetaxel—prostate cancer	7.36e-05	0.000198	CcSEcCtD
Gadobenate Dimeglumine—Haematuria—Doxorubicin—prostate cancer	7.35e-05	0.000197	CcSEcCtD
Gadobenate Dimeglumine—Connective tissue disorder—Epirubicin—prostate cancer	7.35e-05	0.000197	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet degranulation—IGF1—prostate cancer	7.34e-05	0.00261	CbGpPWpGaD
Gadobenate Dimeglumine—Urethral disorder—Epirubicin—prostate cancer	7.33e-05	0.000197	CcSEcCtD
Gadobenate Dimeglumine—Loss of consciousness—Prednisone—prostate cancer	7.32e-05	0.000197	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Estradiol—prostate cancer	7.27e-05	0.000195	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Mitoxantrone—prostate cancer	7.25e-05	0.000195	CcSEcCtD
Gadobenate Dimeglumine—Visual impairment—Epirubicin—prostate cancer	7.21e-05	0.000194	CcSEcCtD
Gadobenate Dimeglumine—Hypertension—Prednisone—prostate cancer	7.19e-05	0.000193	CcSEcCtD
Gadobenate Dimeglumine—Rash—Mitoxantrone—prostate cancer	7.19e-05	0.000193	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Mitoxantrone—prostate cancer	7.18e-05	0.000193	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.18e-05	0.000193	CcSEcCtD
Gadobenate Dimeglumine—Headache—Mitoxantrone—prostate cancer	7.14e-05	0.000192	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Capecitabine—prostate cancer	7.13e-05	0.000191	CcSEcCtD
Gadobenate Dimeglumine—Arthralgia—Prednisone—prostate cancer	7.09e-05	0.00019	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Prednisone—prostate cancer	7.09e-05	0.00019	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Docetaxel—prostate cancer	7.08e-05	0.00019	CcSEcCtD
Gadobenate Dimeglumine—Anxiety—Prednisone—prostate cancer	7.06e-05	0.00019	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—HPGD—prostate cancer	7.06e-05	0.00251	CbGpPWpGaD
Gadobenate Dimeglumine—Bradycardia—Doxorubicin—prostate cancer	7.05e-05	0.000189	CcSEcCtD
Gadobenate Dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.04e-05	0.000189	CcSEcCtD
Gadobenate Dimeglumine—ALB—Selenium Micronutrient Network—INS—prostate cancer	7.03e-05	0.0025	CbGpPWpGaD
Gadobenate Dimeglumine—Dyspnoea—Docetaxel—prostate cancer	7.03e-05	0.000189	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—THBS1—prostate cancer	7.01e-05	0.00249	CbGpPWpGaD
Gadobenate Dimeglumine—Somnolence—Docetaxel—prostate cancer	7.01e-05	0.000188	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Prednisone—prostate cancer	7e-05	0.000188	CcSEcCtD
Gadobenate Dimeglumine—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—prostate cancer	6.99e-05	0.00248	CbGpPWpGaD
Gadobenate Dimeglumine—Eye disorder—Epirubicin—prostate cancer	6.99e-05	0.000188	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Etoposide—prostate cancer	6.99e-05	0.000188	CcSEcCtD
Gadobenate Dimeglumine—Tinnitus—Epirubicin—prostate cancer	6.98e-05	0.000187	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet degranulation—SERPINE1—prostate cancer	6.97e-05	0.00248	CbGpPWpGaD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.95e-05	0.000187	CcSEcCtD
Gadobenate Dimeglumine—Flushing—Epirubicin—prostate cancer	6.94e-05	0.000186	CcSEcCtD
Gadobenate Dimeglumine—Cardiac disorder—Epirubicin—prostate cancer	6.94e-05	0.000186	CcSEcCtD
Gadobenate Dimeglumine—Rhinitis—Doxorubicin—prostate cancer	6.94e-05	0.000186	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Docetaxel—prostate cancer	6.94e-05	0.000186	CcSEcCtD
Gadobenate Dimeglumine—Hypoaesthesia—Doxorubicin—prostate cancer	6.89e-05	0.000185	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Capecitabine—prostate cancer	6.85e-05	0.000184	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract disorder—Doxorubicin—prostate cancer	6.84e-05	0.000184	CcSEcCtD
Gadobenate Dimeglumine—Oedema peripheral—Doxorubicin—prostate cancer	6.82e-05	0.000183	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Docetaxel—prostate cancer	6.8e-05	0.000183	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Etoposide—prostate cancer	6.8e-05	0.000183	CcSEcCtD
Gadobenate Dimeglumine—Connective tissue disorder—Doxorubicin—prostate cancer	6.8e-05	0.000183	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Capecitabine—prostate cancer	6.8e-05	0.000183	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Prednisone—prostate cancer	6.8e-05	0.000183	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Docetaxel—prostate cancer	6.79e-05	0.000182	CcSEcCtD
Gadobenate Dimeglumine—Angiopathy—Epirubicin—prostate cancer	6.79e-05	0.000182	CcSEcCtD
Gadobenate Dimeglumine—Urethral disorder—Doxorubicin—prostate cancer	6.79e-05	0.000182	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—PRKCZ—prostate cancer	6.78e-05	0.00241	CbGpPWpGaD
Gadobenate Dimeglumine—Nausea—Mitoxantrone—prostate cancer	6.77e-05	0.000182	CcSEcCtD
Gadobenate Dimeglumine—Immune system disorder—Epirubicin—prostate cancer	6.76e-05	0.000181	CcSEcCtD
Gadobenate Dimeglumine—Infection—Prednisone—prostate cancer	6.75e-05	0.000181	CcSEcCtD
Gadobenate Dimeglumine—Mediastinal disorder—Epirubicin—prostate cancer	6.74e-05	0.000181	CcSEcCtD
Gadobenate Dimeglumine—Pain—Docetaxel—prostate cancer	6.74e-05	0.000181	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Docetaxel—prostate cancer	6.74e-05	0.000181	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Capecitabine—prostate cancer	6.72e-05	0.00018	CcSEcCtD
Gadobenate Dimeglumine—Chills—Epirubicin—prostate cancer	6.71e-05	0.00018	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Etoposide—prostate cancer	6.71e-05	0.00018	CcSEcCtD
Gadobenate Dimeglumine—Shock—Prednisone—prostate cancer	6.69e-05	0.00018	CcSEcCtD
Gadobenate Dimeglumine—Arrhythmia—Epirubicin—prostate cancer	6.68e-05	0.000179	CcSEcCtD
Gadobenate Dimeglumine—Visual impairment—Doxorubicin—prostate cancer	6.67e-05	0.000179	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Prednisone—prostate cancer	6.66e-05	0.000179	CcSEcCtD
Gadobenate Dimeglumine—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—prostate cancer	6.64e-05	0.00236	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—TNFRSF21—prostate cancer	6.64e-05	0.00236	CbGpPWpGaD
Gadobenate Dimeglumine—Tachycardia—Prednisone—prostate cancer	6.63e-05	0.000178	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Prednisone—prostate cancer	6.6e-05	0.000177	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Capecitabine—prostate cancer	6.59e-05	0.000177	CcSEcCtD
Gadobenate Dimeglumine—ALB—Folate Metabolism—IL2—prostate cancer	6.58e-05	0.00234	CbGpPWpGaD
Gadobenate Dimeglumine—Fatigue—Capecitabine—prostate cancer	6.58e-05	0.000177	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Prednisone—prostate cancer	6.57e-05	0.000176	CcSEcCtD
Gadobenate Dimeglumine—Mental disorder—Epirubicin—prostate cancer	6.55e-05	0.000176	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Capecitabine—prostate cancer	6.52e-05	0.000175	CcSEcCtD
Gadobenate Dimeglumine—Pain—Capecitabine—prostate cancer	6.52e-05	0.000175	CcSEcCtD
Gadobenate Dimeglumine—Erythema—Epirubicin—prostate cancer	6.51e-05	0.000175	CcSEcCtD
Gadobenate Dimeglumine—Malnutrition—Epirubicin—prostate cancer	6.51e-05	0.000175	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Docetaxel—prostate cancer	6.49e-05	0.000174	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Etoposide—prostate cancer	6.49e-05	0.000174	CcSEcCtD
Gadobenate Dimeglumine—Eye disorder—Doxorubicin—prostate cancer	6.47e-05	0.000174	CcSEcCtD
Gadobenate Dimeglumine—ALB—Selenium Micronutrient Network—SERPINE1—prostate cancer	6.46e-05	0.00229	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—CYP7B1—prostate cancer	6.46e-05	0.00229	CbGpPWpGaD
Gadobenate Dimeglumine—Tinnitus—Doxorubicin—prostate cancer	6.45e-05	0.000173	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Docetaxel—prostate cancer	6.44e-05	0.000173	CcSEcCtD
Gadobenate Dimeglumine—Cardiac disorder—Doxorubicin—prostate cancer	6.42e-05	0.000173	CcSEcCtD
Gadobenate Dimeglumine—Flushing—Doxorubicin—prostate cancer	6.42e-05	0.000173	CcSEcCtD
Gadobenate Dimeglumine—Dysgeusia—Epirubicin—prostate cancer	6.38e-05	0.000171	CcSEcCtD
Gadobenate Dimeglumine—Back pain—Epirubicin—prostate cancer	6.3e-05	0.000169	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—SRD5A1—prostate cancer	6.3e-05	0.00224	CbGpPWpGaD
Gadobenate Dimeglumine—Feeling abnormal—Capecitabine—prostate cancer	6.29e-05	0.000169	CcSEcCtD
Gadobenate Dimeglumine—Angiopathy—Doxorubicin—prostate cancer	6.28e-05	0.000169	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Etoposide—prostate cancer	6.27e-05	0.000168	CcSEcCtD
Gadobenate Dimeglumine—Muscle spasms—Epirubicin—prostate cancer	6.26e-05	0.000168	CcSEcCtD
Gadobenate Dimeglumine—Immune system disorder—Doxorubicin—prostate cancer	6.25e-05	0.000168	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Capecitabine—prostate cancer	6.24e-05	0.000168	CcSEcCtD
Gadobenate Dimeglumine—Mediastinal disorder—Doxorubicin—prostate cancer	6.24e-05	0.000168	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Docetaxel—prostate cancer	6.23e-05	0.000167	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Docetaxel—prostate cancer	6.23e-05	0.000167	CcSEcCtD
Gadobenate Dimeglumine—Chills—Doxorubicin—prostate cancer	6.21e-05	0.000167	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Prednisone—prostate cancer	6.19e-05	0.000166	CcSEcCtD
Gadobenate Dimeglumine—Arrhythmia—Doxorubicin—prostate cancer	6.18e-05	0.000166	CcSEcCtD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—CYP7B1—prostate cancer	6.14e-05	0.00218	CbGpPWpGaD
Gadobenate Dimeglumine—Paraesthesia—Prednisone—prostate cancer	6.1e-05	0.000164	CcSEcCtD
Gadobenate Dimeglumine—Mental disorder—Doxorubicin—prostate cancer	6.06e-05	0.000163	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Capecitabine—prostate cancer	6.06e-05	0.000163	CcSEcCtD
Gadobenate Dimeglumine—Ill-defined disorder—Epirubicin—prostate cancer	6.04e-05	0.000162	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Capecitabine—prostate cancer	6.03e-05	0.000162	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Capecitabine—prostate cancer	6.03e-05	0.000162	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Etoposide—prostate cancer	6.03e-05	0.000162	CcSEcCtD
Gadobenate Dimeglumine—Malnutrition—Doxorubicin—prostate cancer	6.03e-05	0.000162	CcSEcCtD
Gadobenate Dimeglumine—Erythema—Doxorubicin—prostate cancer	6.03e-05	0.000162	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Epirubicin—prostate cancer	6.02e-05	0.000162	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—HSD17B3—prostate cancer	6.01e-05	0.00213	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—ACSL4—prostate cancer	6.01e-05	0.00213	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—SLC26A4—prostate cancer	5.99e-05	0.00213	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—SLC12A2—prostate cancer	5.99e-05	0.00213	CbGpPWpGaD
Gadobenate Dimeglumine—Dyspepsia—Prednisone—prostate cancer	5.98e-05	0.000161	CcSEcCtD
Gadobenate Dimeglumine—Rash—Etoposide—prostate cancer	5.98e-05	0.000161	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Etoposide—prostate cancer	5.97e-05	0.00016	CcSEcCtD
Gadobenate Dimeglumine—Headache—Etoposide—prostate cancer	5.94e-05	0.00016	CcSEcCtD
Gadobenate Dimeglumine—Dysgeusia—Doxorubicin—prostate cancer	5.9e-05	0.000158	CcSEcCtD
Gadobenate Dimeglumine—ALB—Hemostasis—ITGA6—prostate cancer	5.88e-05	0.00209	CbGpPWpGaD
Gadobenate Dimeglumine—Malaise—Epirubicin—prostate cancer	5.87e-05	0.000158	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Prednisone—prostate cancer	5.86e-05	0.000157	CcSEcCtD
Gadobenate Dimeglumine—Syncope—Epirubicin—prostate cancer	5.84e-05	0.000157	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Epirubicin—prostate cancer	5.83e-05	0.000157	CcSEcCtD
Gadobenate Dimeglumine—Back pain—Doxorubicin—prostate cancer	5.83e-05	0.000157	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Prednisone—prostate cancer	5.81e-05	0.000156	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Docetaxel—prostate cancer	5.81e-05	0.000156	CcSEcCtD
Gadobenate Dimeglumine—Muscle spasms—Doxorubicin—prostate cancer	5.79e-05	0.000156	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—PRKCQ—prostate cancer	5.77e-05	0.00205	CbGpPWpGaD
Gadobenate Dimeglumine—Palpitations—Epirubicin—prostate cancer	5.76e-05	0.000155	CcSEcCtD
Gadobenate Dimeglumine—Loss of consciousness—Epirubicin—prostate cancer	5.72e-05	0.000154	CcSEcCtD
Gadobenate Dimeglumine—Cough—Epirubicin—prostate cancer	5.68e-05	0.000153	CcSEcCtD
Gadobenate Dimeglumine—ALB—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	5.68e-05	0.00202	CbGpPWpGaD
Gadobenate Dimeglumine—Asthenia—Docetaxel—prostate cancer	5.65e-05	0.000152	CcSEcCtD
Gadobenate Dimeglumine—ALB—Selenium Micronutrient Network—PTGS2—prostate cancer	5.64e-05	0.002	CbGpPWpGaD
Gadobenate Dimeglumine—Nausea—Etoposide—prostate cancer	5.63e-05	0.000151	CcSEcCtD
Gadobenate Dimeglumine—Hypertension—Epirubicin—prostate cancer	5.62e-05	0.000151	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Capecitabine—prostate cancer	5.62e-05	0.000151	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Prednisone—prostate cancer	5.6e-05	0.00015	CcSEcCtD
Gadobenate Dimeglumine—Ill-defined disorder—Doxorubicin—prostate cancer	5.59e-05	0.00015	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Docetaxel—prostate cancer	5.58e-05	0.00015	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Doxorubicin—prostate cancer	5.57e-05	0.00015	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Prednisone—prostate cancer	5.56e-05	0.000149	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Epirubicin—prostate cancer	5.54e-05	0.000149	CcSEcCtD
Gadobenate Dimeglumine—Chest pain—Epirubicin—prostate cancer	5.54e-05	0.000149	CcSEcCtD
Gadobenate Dimeglumine—Arthralgia—Epirubicin—prostate cancer	5.54e-05	0.000149	CcSEcCtD
Gadobenate Dimeglumine—ALB—Hemostasis—CD9—prostate cancer	5.53e-05	0.00196	CbGpPWpGaD
Gadobenate Dimeglumine—Anxiety—Epirubicin—prostate cancer	5.53e-05	0.000148	CcSEcCtD
Gadobenate Dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.51e-05	0.000148	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Epirubicin—prostate cancer	5.48e-05	0.000147	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism—HAO1—prostate cancer	5.48e-05	0.00194	CbGpPWpGaD
Gadobenate Dimeglumine—Asthenia—Capecitabine—prostate cancer	5.47e-05	0.000147	CcSEcCtD
Gadobenate Dimeglumine—Malaise—Doxorubicin—prostate cancer	5.43e-05	0.000146	CcSEcCtD
Gadobenate Dimeglumine—Dry mouth—Epirubicin—prostate cancer	5.42e-05	0.000146	CcSEcCtD
Gadobenate Dimeglumine—Syncope—Doxorubicin—prostate cancer	5.4e-05	0.000145	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Prednisone—prostate cancer	5.4e-05	0.000145	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Capecitabine—prostate cancer	5.4e-05	0.000145	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Doxorubicin—prostate cancer	5.39e-05	0.000145	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Docetaxel—prostate cancer	5.39e-05	0.000145	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Prednisone—prostate cancer	5.37e-05	0.000144	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Prednisone—prostate cancer	5.37e-05	0.000144	CcSEcCtD
Gadobenate Dimeglumine—Confusional state—Epirubicin—prostate cancer	5.36e-05	0.000144	CcSEcCtD
Gadobenate Dimeglumine—Palpitations—Doxorubicin—prostate cancer	5.33e-05	0.000143	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Epirubicin—prostate cancer	5.32e-05	0.000143	CcSEcCtD
Gadobenate Dimeglumine—Loss of consciousness—Doxorubicin—prostate cancer	5.3e-05	0.000142	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—VAV3—prostate cancer	5.29e-05	0.00188	CbGpPWpGaD
Gadobenate Dimeglumine—Infection—Epirubicin—prostate cancer	5.28e-05	0.000142	CcSEcCtD
Gadobenate Dimeglumine—Cough—Doxorubicin—prostate cancer	5.26e-05	0.000141	CcSEcCtD
Gadobenate Dimeglumine—Shock—Epirubicin—prostate cancer	5.23e-05	0.00014	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Capecitabine—prostate cancer	5.22e-05	0.00014	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Epirubicin—prostate cancer	5.21e-05	0.00014	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Docetaxel—prostate cancer	5.21e-05	0.00014	CcSEcCtD
Gadobenate Dimeglumine—Hypertension—Doxorubicin—prostate cancer	5.2e-05	0.00014	CcSEcCtD
Gadobenate Dimeglumine—Tachycardia—Epirubicin—prostate cancer	5.19e-05	0.000139	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Epirubicin—prostate cancer	5.16e-05	0.000139	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Epirubicin—prostate cancer	5.14e-05	0.000138	CcSEcCtD
Gadobenate Dimeglumine—Chest pain—Doxorubicin—prostate cancer	5.13e-05	0.000138	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Doxorubicin—prostate cancer	5.13e-05	0.000138	CcSEcCtD
Gadobenate Dimeglumine—Arthralgia—Doxorubicin—prostate cancer	5.13e-05	0.000138	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—ITPR1—prostate cancer	5.13e-05	0.00182	CbGpPWpGaD
Gadobenate Dimeglumine—Anxiety—Doxorubicin—prostate cancer	5.11e-05	0.000137	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—HSD3B1—prostate cancer	5.11e-05	0.00181	CbGpPWpGaD
Gadobenate Dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.09e-05	0.000137	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Doxorubicin—prostate cancer	5.07e-05	0.000136	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Capecitabine—prostate cancer	5.05e-05	0.000135	CcSEcCtD
Gadobenate Dimeglumine—Dry mouth—Doxorubicin—prostate cancer	5.02e-05	0.000135	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Docetaxel—prostate cancer	5.01e-05	0.000135	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Prednisone—prostate cancer	5.01e-05	0.000134	CcSEcCtD
Gadobenate Dimeglumine—ALB—Hemostasis—CLU—prostate cancer	5e-05	0.00178	CbGpPWpGaD
Gadobenate Dimeglumine—Rash—Docetaxel—prostate cancer	4.97e-05	0.000133	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Epirubicin—prostate cancer	4.97e-05	0.000133	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Docetaxel—prostate cancer	4.96e-05	0.000133	CcSEcCtD
Gadobenate Dimeglumine—Confusional state—Doxorubicin—prostate cancer	4.96e-05	0.000133	CcSEcCtD
Gadobenate Dimeglumine—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—prostate cancer	4.94e-05	0.00175	CbGpPWpGaD
Gadobenate Dimeglumine—Headache—Docetaxel—prostate cancer	4.94e-05	0.000133	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Doxorubicin—prostate cancer	4.92e-05	0.000132	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—TBXAS1—prostate cancer	4.9e-05	0.00174	CbGpPWpGaD
Gadobenate Dimeglumine—Infection—Doxorubicin—prostate cancer	4.89e-05	0.000131	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Prednisone—prostate cancer	4.88e-05	0.000131	CcSEcCtD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—SLC22A3—prostate cancer	4.86e-05	0.00172	CbGpPWpGaD
Gadobenate Dimeglumine—Vomiting—Capecitabine—prostate cancer	4.85e-05	0.00013	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.84e-05	0.00013	CcSEcCtD
Gadobenate Dimeglumine—Shock—Doxorubicin—prostate cancer	4.84e-05	0.00013	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Doxorubicin—prostate cancer	4.82e-05	0.00013	CcSEcCtD
Gadobenate Dimeglumine—Rash—Capecitabine—prostate cancer	4.81e-05	0.000129	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Prednisone—prostate cancer	4.81e-05	0.000129	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Capecitabine—prostate cancer	4.81e-05	0.000129	CcSEcCtD
Gadobenate Dimeglumine—Tachycardia—Doxorubicin—prostate cancer	4.8e-05	0.000129	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet degranulation—VEGFA—prostate cancer	4.8e-05	0.0017	CbGpPWpGaD
Gadobenate Dimeglumine—Headache—Capecitabine—prostate cancer	4.78e-05	0.000128	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Doxorubicin—prostate cancer	4.78e-05	0.000128	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Epirubicin—prostate cancer	4.77e-05	0.000128	CcSEcCtD
Gadobenate Dimeglumine—ALB—Vitamin B12 Metabolism—IL6—prostate cancer	4.76e-05	0.00169	CbGpPWpGaD
Gadobenate Dimeglumine—Hyperhidrosis—Doxorubicin—prostate cancer	4.75e-05	0.000128	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Epirubicin—prostate cancer	4.74e-05	0.000127	CcSEcCtD
Gadobenate Dimeglumine—Somnolence—Epirubicin—prostate cancer	4.73e-05	0.000127	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—ABCG5—prostate cancer	4.71e-05	0.00167	CbGpPWpGaD
Gadobenate Dimeglumine—Nausea—Docetaxel—prostate cancer	4.68e-05	0.000126	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Epirubicin—prostate cancer	4.68e-05	0.000126	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Prednisone—prostate cancer	4.65e-05	0.000125	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Doxorubicin—prostate cancer	4.6e-05	0.000123	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Epirubicin—prostate cancer	4.59e-05	0.000123	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Epirubicin—prostate cancer	4.58e-05	0.000123	CcSEcCtD
Gadobenate Dimeglumine—ALB—Hemostasis—GRB7—prostate cancer	4.57e-05	0.00162	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—prostate cancer	4.57e-05	0.00162	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—HSD3B2—prostate cancer	4.55e-05	0.00162	CbGpPWpGaD
Gadobenate Dimeglumine—Constipation—Epirubicin—prostate cancer	4.55e-05	0.000122	CcSEcCtD
Gadobenate Dimeglumine—Pain—Epirubicin—prostate cancer	4.55e-05	0.000122	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—ITGB3—prostate cancer	4.54e-05	0.00161	CbGpPWpGaD
Gadobenate Dimeglumine—Nausea—Capecitabine—prostate cancer	4.53e-05	0.000122	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Prednisone—prostate cancer	4.49e-05	0.000121	CcSEcCtD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—ABCG5—prostate cancer	4.48e-05	0.00159	CbGpPWpGaD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.48e-05	0.00012	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism—CSAD—prostate cancer	4.46e-05	0.00159	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GRHL1—prostate cancer	4.46e-05	0.00159	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PSAT1—prostate cancer	4.46e-05	0.00159	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—TST—prostate cancer	4.46e-05	0.00159	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—ADI1—prostate cancer	4.46e-05	0.00159	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CBR1—prostate cancer	4.46e-05	0.00159	CbGpPWpGaD
Gadobenate Dimeglumine—Paraesthesia—Doxorubicin—prostate cancer	4.42e-05	0.000119	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet degranulation—TGFB1—prostate cancer	4.4e-05	0.00156	CbGpPWpGaD
Gadobenate Dimeglumine—Dyspnoea—Doxorubicin—prostate cancer	4.38e-05	0.000118	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Epirubicin—prostate cancer	4.38e-05	0.000118	CcSEcCtD
Gadobenate Dimeglumine—Somnolence—Doxorubicin—prostate cancer	4.37e-05	0.000117	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—LRP2—prostate cancer	4.36e-05	0.00155	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—GNG5—prostate cancer	4.35e-05	0.00154	CbGpPWpGaD
Gadobenate Dimeglumine—Gastrointestinal pain—Epirubicin—prostate cancer	4.35e-05	0.000117	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Doxorubicin—prostate cancer	4.33e-05	0.000116	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Prednisone—prostate cancer	4.32e-05	0.000116	CcSEcCtD
Gadobenate Dimeglumine—Rash—Prednisone—prostate cancer	4.28e-05	0.000115	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Prednisone—prostate cancer	4.28e-05	0.000115	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—P4HB—prostate cancer	4.28e-05	0.00152	CbGpPWpGaD
Gadobenate Dimeglumine—Headache—Prednisone—prostate cancer	4.26e-05	0.000114	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.25e-05	0.000114	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Doxorubicin—prostate cancer	4.24e-05	0.000114	CcSEcCtD
Gadobenate Dimeglumine—ALB—Folate Metabolism—TP53—prostate cancer	4.23e-05	0.0015	CbGpPWpGaD
Gadobenate Dimeglumine—Urticaria—Epirubicin—prostate cancer	4.22e-05	0.000113	CcSEcCtD
Gadobenate Dimeglumine—Pain—Doxorubicin—prostate cancer	4.21e-05	0.000113	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Doxorubicin—prostate cancer	4.21e-05	0.000113	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Epirubicin—prostate cancer	4.2e-05	0.000113	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Epirubicin—prostate cancer	4.2e-05	0.000113	CcSEcCtD
Gadobenate Dimeglumine—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—prostate cancer	4.19e-05	0.00149	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CKMT2—prostate cancer	4.15e-05	0.00147	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—UGT2B15—prostate cancer	4.15e-05	0.00147	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GRHPR—prostate cancer	4.15e-05	0.00147	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—UGT2B17—prostate cancer	4.15e-05	0.00147	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	4.06e-05	0.00144	CbGpPWpGaD
Gadobenate Dimeglumine—Feeling abnormal—Doxorubicin—prostate cancer	4.05e-05	0.000109	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Prednisone—prostate cancer	4.04e-05	0.000108	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Doxorubicin—prostate cancer	4.02e-05	0.000108	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—MED12—prostate cancer	3.99e-05	0.00142	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—SLC22A1—prostate cancer	3.96e-05	0.00141	CbGpPWpGaD
Gadobenate Dimeglumine—Hypersensitivity—Epirubicin—prostate cancer	3.92e-05	0.000105	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Doxorubicin—prostate cancer	3.91e-05	0.000105	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism—PGAM2—prostate cancer	3.9e-05	0.00139	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—SULT2B1—prostate cancer	3.9e-05	0.00139	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GSTM3—prostate cancer	3.9e-05	0.00139	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—AOX1—prostate cancer	3.9e-05	0.00139	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—MBTPS1—prostate cancer	3.9e-05	0.00139	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—RFK—prostate cancer	3.9e-05	0.00139	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—NAGLU—prostate cancer	3.9e-05	0.00139	CbGpPWpGaD
Gadobenate Dimeglumine—Abdominal pain—Doxorubicin—prostate cancer	3.89e-05	0.000104	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Doxorubicin—prostate cancer	3.89e-05	0.000104	CcSEcCtD
Gadobenate Dimeglumine—ALB—Folate Metabolism—IL6—prostate cancer	3.87e-05	0.00137	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	3.81e-05	0.00135	CbGpPWpGaD
Gadobenate Dimeglumine—Asthenia—Epirubicin—prostate cancer	3.81e-05	0.000102	CcSEcCtD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—GNG5—prostate cancer	3.77e-05	0.00134	CbGpPWpGaD
Gadobenate Dimeglumine—Pruritus—Epirubicin—prostate cancer	3.76e-05	0.000101	CcSEcCtD
Gadobenate Dimeglumine—ALB—Hemostasis—PRKACB—prostate cancer	3.71e-05	0.00132	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—AMACR—prostate cancer	3.7e-05	0.00131	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP3A43—prostate cancer	3.7e-05	0.00131	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—NAT1—prostate cancer	3.7e-05	0.00131	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—SRD5A2—prostate cancer	3.7e-05	0.00131	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—DEGS1—prostate cancer	3.7e-05	0.00131	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	3.64e-05	0.00129	CbGpPWpGaD
Gadobenate Dimeglumine—Diarrhoea—Epirubicin—prostate cancer	3.64e-05	9.77e-05	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Doxorubicin—prostate cancer	3.62e-05	9.73e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	3.62e-05	0.00128	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—THBS1—prostate cancer	3.61e-05	0.00128	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—PIK3CG—prostate cancer	3.56e-05	0.00126	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—HSD17B1—prostate cancer	3.53e-05	0.00125	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	3.53e-05	0.00125	CbGpPWpGaD
Gadobenate Dimeglumine—Asthenia—Doxorubicin—prostate cancer	3.53e-05	9.48e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—EGF—prostate cancer	3.52e-05	0.00125	CbGpPWpGaD
Gadobenate Dimeglumine—Dizziness—Epirubicin—prostate cancer	3.51e-05	9.44e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Hemostasis—PRKCZ—prostate cancer	3.5e-05	0.00124	CbGpPWpGaD
Gadobenate Dimeglumine—Pruritus—Doxorubicin—prostate cancer	3.48e-05	9.34e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	3.39e-05	0.0012	CbGpPWpGaD
Gadobenate Dimeglumine—Vomiting—Epirubicin—prostate cancer	3.38e-05	9.08e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	3.38e-05	0.0012	CbGpPWpGaD
Gadobenate Dimeglumine—Diarrhoea—Doxorubicin—prostate cancer	3.36e-05	9.04e-05	CcSEcCtD
Gadobenate Dimeglumine—Rash—Epirubicin—prostate cancer	3.35e-05	9e-05	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Epirubicin—prostate cancer	3.35e-05	8.99e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	3.34e-05	0.00119	CbGpPWpGaD
Gadobenate Dimeglumine—Headache—Epirubicin—prostate cancer	3.33e-05	8.94e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—IGF1—prostate cancer	3.26e-05	0.00116	CbGpPWpGaD
Gadobenate Dimeglumine—Dizziness—Doxorubicin—prostate cancer	3.25e-05	8.73e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—PRKACB—prostate cancer	3.21e-05	0.00114	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	3.18e-05	0.00113	CbGpPWpGaD
Gadobenate Dimeglumine—Nausea—Epirubicin—prostate cancer	3.16e-05	8.48e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Metabolism—B4GALT4—prostate cancer	3.15e-05	0.00112	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—HPGD—prostate cancer	3.15e-05	0.00112	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—PIK3CD—prostate cancer	3.13e-05	0.00111	CbGpPWpGaD
Gadobenate Dimeglumine—Vomiting—Doxorubicin—prostate cancer	3.13e-05	8.4e-05	CcSEcCtD
Gadobenate Dimeglumine—Rash—Doxorubicin—prostate cancer	3.1e-05	8.33e-05	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Doxorubicin—prostate cancer	3.1e-05	8.32e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—SERPINE1—prostate cancer	3.09e-05	0.0011	CbGpPWpGaD
Gadobenate Dimeglumine—Headache—Doxorubicin—prostate cancer	3.08e-05	8.27e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Selenium Micronutrient Network—IL6—prostate cancer	3.07e-05	0.00109	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—NCOA2—prostate cancer	3.03e-05	0.00107	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—PRKCQ—prostate cancer	2.97e-05	0.00106	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—TNFRSF21—prostate cancer	2.96e-05	0.00105	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—PLAUR—prostate cancer	2.94e-05	0.00104	CbGpPWpGaD
Gadobenate Dimeglumine—Nausea—Doxorubicin—prostate cancer	2.92e-05	7.85e-05	CcSEcCtD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—SLC5A5—prostate cancer	2.89e-05	0.00103	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—MTAP—prostate cancer	2.88e-05	0.00102	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP7B1—prostate cancer	2.88e-05	0.00102	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—JAK2—prostate cancer	2.87e-05	0.00102	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	2.81e-05	0.000998	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—SULT1E1—prostate cancer	2.8e-05	0.000995	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—SRD5A1—prostate cancer	2.8e-05	0.000995	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—VAV3—prostate cancer	2.73e-05	0.000968	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—PIK3CB—prostate cancer	2.73e-05	0.000968	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	2.72e-05	0.000967	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	2.68e-05	0.000952	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—ACSL4—prostate cancer	2.67e-05	0.00095	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—HSD17B3—prostate cancer	2.67e-05	0.00095	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—ITPR1—prostate cancer	2.64e-05	0.000939	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	2.64e-05	0.000939	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PHGDH—prostate cancer	2.56e-05	0.00091	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—ARG2—prostate cancer	2.56e-05	0.00091	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—UMPS—prostate cancer	2.56e-05	0.00091	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	2.55e-05	0.000906	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—NCOA1—prostate cancer	2.55e-05	0.000906	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—LDHB—prostate cancer	2.51e-05	0.000893	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—IL2—prostate cancer	2.5e-05	0.000889	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP3A5—prostate cancer	2.47e-05	0.000876	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—RXRA—prostate cancer	2.43e-05	0.000861	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PDHA1—prostate cancer	2.38e-05	0.000846	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—UCP3—prostate cancer	2.38e-05	0.000846	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GSTA3—prostate cancer	2.38e-05	0.000846	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—TCN2—prostate cancer	2.38e-05	0.000846	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—ITGB3—prostate cancer	2.34e-05	0.000831	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—HSD3B1—prostate cancer	2.27e-05	0.000807	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—SLC22A3—prostate cancer	2.27e-05	0.000807	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—LPL—prostate cancer	2.21e-05	0.000783	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—SRC—prostate cancer	2.18e-05	0.000775	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—TBXAS1—prostate cancer	2.18e-05	0.000774	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GSTA4—prostate cancer	2.18e-05	0.000774	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	2.13e-05	0.000757	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—VEGFA—prostate cancer	2.13e-05	0.000755	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GSTA2—prostate cancer	2.12e-05	0.000754	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—SULT1A1—prostate cancer	2.1e-05	0.000745	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—ABCG5—prostate cancer	2.1e-05	0.000745	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—PLAU—prostate cancer	2.06e-05	0.000732	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GSTA1—prostate cancer	2.05e-05	0.000728	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—HSD3B2—prostate cancer	2.03e-05	0.00072	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GSTO1—prostate cancer	2.03e-05	0.00072	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—NAT2—prostate cancer	2.03e-05	0.00072	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—CAV1—prostate cancer	2.01e-05	0.000715	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—TGFB1—prostate cancer	1.95e-05	0.000693	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.95e-05	0.000692	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PLCB2—prostate cancer	1.94e-05	0.00069	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP2C18—prostate cancer	1.94e-05	0.00069	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—LRP2—prostate cancer	1.94e-05	0.00069	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—P4HB—prostate cancer	1.91e-05	0.000677	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—SLC22A1—prostate cancer	1.85e-05	0.000658	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—PPARA—prostate cancer	1.85e-05	0.000658	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—PIK3CG—prostate cancer	1.83e-05	0.000651	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.83e-05	0.000651	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—EGF—prostate cancer	1.81e-05	0.000643	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—SULT2A1—prostate cancer	1.81e-05	0.000641	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—MED12—prostate cancer	1.78e-05	0.000631	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GNG5—prostate cancer	1.76e-05	0.000626	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—CREBBP—prostate cancer	1.7e-05	0.000604	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—NCOA3—prostate cancer	1.7e-05	0.000603	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—IGF1—prostate cancer	1.68e-05	0.000596	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.67e-05	0.000593	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—PIK3CA—prostate cancer	1.66e-05	0.00059	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—HPGDS—prostate cancer	1.62e-05	0.000575	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—PIK3CD—prostate cancer	1.61e-05	0.000572	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP2C19—prostate cancer	1.61e-05	0.000572	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—SERPINE1—prostate cancer	1.59e-05	0.000566	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GSTT1—prostate cancer	1.57e-05	0.000558	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—ACHE—prostate cancer	1.57e-05	0.000558	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP2A6—prostate cancer	1.55e-05	0.000552	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.55e-05	0.000549	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—NOS3—prostate cancer	1.52e-05	0.00054	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—AKR1C3—prostate cancer	1.51e-05	0.000537	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PRKACB—prostate cancer	1.5e-05	0.000534	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP17A1—prostate cancer	1.49e-05	0.000528	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—JAK2—prostate cancer	1.48e-05	0.000525	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.47e-05	0.000522	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.47e-05	0.000521	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—NCOA2—prostate cancer	1.42e-05	0.000503	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—PIK3CB—prostate cancer	1.4e-05	0.000499	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	1.36e-05	0.000482	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—SLC5A5—prostate cancer	1.35e-05	0.00048	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP2E1—prostate cancer	1.32e-05	0.000469	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—NQO1—prostate cancer	1.31e-05	0.000464	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—IL2—prostate cancer	1.29e-05	0.000458	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—TH—prostate cancer	1.29e-05	0.000457	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.28e-05	0.000454	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP3A4—prostate cancer	1.27e-05	0.000452	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.27e-05	0.00045	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP1B1—prostate cancer	1.25e-05	0.000445	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GGT1—prostate cancer	1.21e-05	0.000431	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—NCOA1—prostate cancer	1.19e-05	0.000424	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP19A1—prostate cancer	1.18e-05	0.000418	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—EP300—prostate cancer	1.16e-05	0.000411	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—RXRA—prostate cancer	1.14e-05	0.000403	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—SRC—prostate cancer	1.13e-05	0.0004	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.11e-05	0.000392	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—VEGFA—prostate cancer	1.1e-05	0.000389	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—COMT—prostate cancer	1.09e-05	0.000389	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GSTP1—prostate cancer	1.09e-05	0.000387	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—ITPR1—prostate cancer	1.07e-05	0.000381	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.05e-05	0.000374	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—TYMS—prostate cancer	1.01e-05	0.00036	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—TGFB1—prostate cancer	1.01e-05	0.000357	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—GSTM1—prostate cancer	1e-05	0.000355	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—LPL—prostate cancer	9.83e-06	0.000349	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CYP1A1—prostate cancer	9.49e-06	0.000337	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—ERCC2—prostate cancer	9.41e-06	0.000334	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—KRAS—prostate cancer	9.32e-06	0.000331	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—MTHFR—prostate cancer	8.85e-06	0.000314	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PPARA—prostate cancer	8.68e-06	0.000308	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—PIK3CA—prostate cancer	8.56e-06	0.000304	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—TP53—prostate cancer	8.29e-06	0.000294	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CAV1—prostate cancer	8.16e-06	0.00029	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.8e-06	0.000277	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PIK3CG—prostate cancer	7.43e-06	0.000264	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—INS—prostate cancer	7.04e-06	0.00025	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Hemostasis—AKT1—prostate cancer	7e-06	0.000248	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—CREBBP—prostate cancer	6.89e-06	0.000245	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PIK3CD—prostate cancer	6.54e-06	0.000232	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—NOS3—prostate cancer	6.17e-06	0.000219	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PIK3CB—prostate cancer	5.7e-06	0.000202	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PTGS2—prostate cancer	5.64e-06	0.0002	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PTEN—prostate cancer	4.92e-06	0.000175	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—EP300—prostate cancer	4.69e-06	0.000167	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—PIK3CA—prostate cancer	3.47e-06	0.000123	CbGpPWpGaD
Gadobenate Dimeglumine—ALB—Metabolism—AKT1—prostate cancer	2.84e-06	0.000101	CbGpPWpGaD
